GTC Biotherapeutics (fka GTCB)

[dodah_2]

I bought a small amount at .87. I'm surprised that Pharming's drug was not approved, especially considering the positive press releases about Rhucin's progress. I believe it's PPs has been higher than GTCB's, in part, because of GTCB's previous approval, and its stockholders imagined approval would be fairly routine. In some respects it's nice to know the EMEA was not biased towards a European submission.